Clinical trials: Pancreas Cancer, open to volunteers
Colorectal Neoplasms, Gastric Neoplasms
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
Background: Recent advances in cancer research have led to new therapies to treat the disease. It is important to continue these advances and discover new ones. To do that, researchers need tissue samples from solid tumors.
- Conditions
- Colorectal Neoplasms, Gastric Neoplasms, Cholangiocarcinoma, Bile Duct Cancer
- Trial name
- NCT01915225
- Where
- United States
- Volunteers
- 1,800 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Adult, Colorectal Cancer
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer
- Trial name
- BASECAMP-1 (NCT04981119)
- Testing
- Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
- Where
- 16 sites in United States
- Volunteers
- 500 people
- Sponsor
- A2 Biotherapeutics Inc.
Pancreas Cancer, Peutz-Jeghers Syndrome (PJS)
The Cancer of the Pancreas Screening-5 CAPS5)Study
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
- Conditions
- Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier
- Trial name
- CAPS5 (NCT02000089)
- Testing
- Secretin, MRI, Tumor marker gene test with CA19-9
- Where
- 9 sites in United States
- Volunteers
- 9,000 people
- Sponsor
- Johns Hopkins University
Pancreas Cancer, Metastatic, Pancreas Cancer, Stage IV
A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer
The goal of this clinical trial is to learn if the new administration regimen of VCN-01, given together with the standard chemotherapy drugs gemcitabine and nab-paclitaxel (GnP), is safe and well tolerated.
- Conditions
- Pancreas Cancer, Metastatic, Pancreas Cancer, Stage IV, Ductal Adenocarcinoma of the Pancreas
- Trial name
- VIRAGE2 (NCT07701486)
- Testing
- VCN-01 oncolytic adenovirus (zabilugene almadenorepvec), Nab-paclitaxel + Gemcitabine
- Where
- Spain
- Volunteers
- 6 people
- Sponsor
- Theriva Biologics SL
Pancreatic Ductal Adenocarcinoma (PDAC), Family History of Pancreas Cancer
Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial
This study will test a remote approach to help people who may be at higher risk for pancreatic cancer learn about and decide whether to get genetic testing and a blood test that looks for signs of several cancers (MCED testing).
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Family History of Pancreas Cancer, Genetic Testing, Multi-cancer Early Detection
- Trial name
- REGENERATE (NCT07787156)
- Testing
- Telephone education session, Online educational materials
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Brigham and Women's Hospital
Non-small Cell Lung Cancer, Pancreas Cancer
T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer
This phase I trial studies the side effects and best dose of autologous CD8+ and CD4+ transgenic T cells expressing high affinity KRASG12V mutation-specific T cell receptors (FH-A11KRASG12V-TCR) and to see how well they work in…
- Conditions
- Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer
- Trial name
- NCT06043713
- Testing
- Bendamustine, Biopsy, Biospecimen Collection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Fred Hutchinson Cancer Center
Ovarian Cancer, Pancreas Cancer
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma.
- Conditions
- Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT06582017
- Testing
- QXL138AM Injection every 2 weeks by IV Infusion
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nammi Therapeutics Inc
Prehabilitation, Pancreas Cancer
Preoperative Optimisation of Modifiable Risk Factors in Surgery of the Pancreas
The goal of this stepped-wedge randomized controlled trial is to investigate whether implementation of a best practice program for preoperative optimisation (prehabilitation program) with a focus on screening, assessment, and…
- Conditions
- Prehabilitation, Pancreas Cancer, Surgery, Postoperative Complications
- Trial name
- PROMISE-P (NCT05851534)
- Testing
- Preoperative optimisation program
- Where
- 13 sites in Netherlands
- Volunteers
- 2,575 people
- Sponsor
- Maastricht University Medical Center
Pancreas Cancer
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
Hypothesis: Survival benefits could be found in Sintilimab plus chemotherapy and radiotherapy in patients with inoperable pancreatic cancer.
- Trial name
- NCT06050317
- Testing
- Sintilimab Plus mFFN or NALIRIFOX and Radiation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shandong Cancer Hospital and Institute
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 28 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Breast Cancer, Corpus Uteri Cancer
INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study
The purpose of the study is to characterize baseline multidisciplinary tumor board (MDTB) context and variability, evaluate the relationship between baseline fitness of patients with cancer and initial treatment recommendations…
- Conditions
- Breast Cancer, Corpus Uteri Cancer, Ovary Cancer, Pancreas Cancer
- Trial name
- INSPIRE (NCT07671937)
- Testing
- INSPIRE (INtegrating Systematic PatIent-Reported Evaluations), Capture of patient-reported outcomes, Enhanced Clinician Awareness
- Where
- 3 sites in United States
- Volunteers
- 2,748 people
- Sponsor
- University of Alabama at Birmingham
Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung
- Trial name
- NCT04429542
- Testing
- BCA101, Pembrolizumab
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 473 people
- Sponsor
- Bicara Therapeutics
Pancreas Cancer, Oligometastatic
Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic…
- Trial name
- NCT06593431
- Testing
- Consolidative Radiation
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer Of Pancreas
Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients
The goal of this interventional study is to learn about the efficacy of first-line chemotherapy with Gemcitabine in metastatic pancreatic adenocarcinoma patients expressing the GemCore signature in their tumor.
- Trial name
- GemSign-01 (NCT06046794)
- Testing
- Analyze of GemCore status
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Institut Paoli-Calmettes
Pancreas Cancer With Hepatic Metastase, Pancreas Adenocarcinoma
Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma
The goal of this observational study is to evaluate whether hepatic artery infusion pump (HAIP) chemotherapy can improve outcomes in patients with pancreatic or duodenal adenocarcinoma who have isolated or liver-dominant…
- Conditions
- Pancreas Cancer With Hepatic Metastase, Pancreas Adenocarcinoma, Duodenal Cancer, Duodenal Adenocarcinoma
- Trial name
- NCT07845617
- Testing
- Hepatic Artery Infusion Pump (HAIP), Floxuridine (FUDR)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- AdventHealth
Pancreatic Cancer, Pancreas Neoplasm
Radiology Registry on Pancreatic Malignancies
The purpose of this study is to collect all radiological data which evaluated with clinical data may help assess malignancy and prognosis of pancreatic disease.This registry aims to collect retrospective data from 2014 and…
- Conditions
- Pancreatic Cancer, Pancreas Neoplasm, Pancreas Disease, Pancreas Cyst
- Trial name
- RadonPams (NCT05714111)
- Testing
- Radiology evaluations and interventions
- Where
- Italy
- Volunteers
- 1,300 people
- Sponsor
- IRCCS San Raffaele
Pancreas Cancer, Duct Cell Adenocarcinoma, Pancreatic Cancer
PHASE 1 TRIAL OF Lm-LLO-TT AND GEMCITABINE IN UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
ClinicalTrials.gov Brief Summary This Phase 1, open-label, first-in-human study is designed to evaluate the safety, tolerability, and recommended dose of intraperitoneal (IP) administration of Lm-LLO-TT in combination with…
- Conditions
- Pancreas Cancer, Duct Cell Adenocarcinoma, Pancreatic Cancer, Advanced Pancreatic Adenocarcinoma
- Trial name
- NCT07828236
- Testing
- Lm-LLO-TT
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Loki Therapeutics, Inc.
Pancreas Cancer, Metastatic, Pancreas Carcinoma
The STRONG Nutrition Support Study for People With Pancreatic Cancer
This single-center pilot randomized controlled trial evaluates the feasibility, acceptability, and preliminary effects of STRONG, a digital nutrition support app delivered alongside remote dietitian-led nutrition counseling, in…
- Trial name
- STRONG (NCT07826780)
- Testing
- STRONG intervention App, individualized remote dietitian
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Pancreas Cancer
Promoting CT Engagement for Pancreatic Cancer With App
To develop a culturally tailored informational mobile application and test whether it will increase participation among Black pancreatic cancer subjects in clinical trial discussions with their care team.
- Trial name
- PROCLAIM (NCT06252545)
- Testing
- semistructured interviews, feedback
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cyst of Pancreas, Pancreatectomy
Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?
The goal of this clinical trial is to analyze if intraperitoneal drainage is necessary following distal pancreatectomy. This study aims to determine whether the omission of routine intraperitoneal drainage in the setting of…
- Conditions
- Cyst of Pancreas, Pancreatectomy, Pancreas Neoplasm
- Trial name
- NCT05720338
- Testing
- 19 French Blake Drain
- Where
- United States
- Volunteers
- 234 people
- Sponsor
- Case Comprehensive Cancer Center